Repros Therapeutics Drops on FDA Vote

By Chris Lange Updated Jan 12, 5:01PM EST · Published Dec 7, 12:05PM EST

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Repros Therapeutics Inc. (NASDAQ: RPRX) saw its shares take a loss on Wednesday after the company provided a key U.S. Food and Drug Administration (FDA) update. The company participated in the industry presentation at the Bone, Reproductive and Urologic Drugs Advisory Committee Meeting on Tuesday, but the results was not favorable.

As we have said time and time again, FDA decisions and clinical trial updates have the potential to make or break companies in the biotech and pharmaceutical industries. 24/7 Wall St. has outlined 10 Major FDA Decisions and Catalysts Expected in December.

The panel provided the FDA with advice regarding a clinical and regulatory path to approval for products, such as enclomiphene, in subjects with obesity-related hypogonadism who wish to maintain spermatogenesis. However, the panel voted 16 to five that the achievement of testosterone improvement while maintaining evidence of spermatogenesis was not sufficient, in and of itself, to provide evidence of clinical benefit.

[nativounit]

At the meeting, numerous panel members suggested that an additional endpoint related to symptoms should be assessed. Repros expects its ongoing diet and exercise study to provide useful information toward the development of a symptom-related assessment tool.

After completing this study and evaluating the data, Repros intends to meet with FDA to discuss the design of a definitive Phase 3 study that incorporates the advice of the committee.

Joe Podolski, president and CEO of Repros, commented:

We remain encouraged that the FDA and the Committee held the committee meeting, indicating a recognition of obesity-related hypogonadism. Further, we appreciate that there was a complete discussion on the condition and that the committee clarified a path forward.

Excluding Wednesday’s move, Repros has outperformed the broad markets, with the stock up about 57% year to date.

Shares of Repros were last seen down about 10% at $1.72 on Wednesday, with a consensus analyst price target of $5.25 and a 52-week trading range of $0.80 to $3.48.

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.